

## Special Issue

# Tailored Molecular and Pathophysiological Approach to COVID-19: Ambition and Need

### Message from the Guest Editor

Common to all SARS-CoV-2 variants is the direct damage to the subtle mechanisms of the renin-angiotensin system that presides over a large part of systemic inflammation and hemodynamics, i.e., the damage to ACE2 (the cell membrane viral receptor) and ACE2-driven angiotensin 1–7 production. Attempts at replacing defective ACE2 or angiotensin 1–7 functions during the clinical course of COVID-19 have been common and pursued all over the world. After two years of pandemic, a tailored and sensible approach to COVID-19 must include: a) a definition of the mechanisms of inflammatory disease that follow cellular infection; b) cognition of the most frequently found viral variants in terms of genomic and antigenic mutations; and c) identification of biomolecular viral and host targets, the latter being the non-classical renin-angiotensin system, that could be acted upon pharmacologically. These aims warrant renewed international and multi-disciplinary efforts.

---

### Guest Editor

Dr. Sansoè Giovanni

Humanitas Institute, Gradenigo Hospital, Torino, Italy

---

### Deadline for manuscript submissions

closed (31 August 2023)



## Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/121032](https://mdpi.com/si/121032)

*Current Issues in Molecular Biology*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cimb@mdpi.com](mailto:cimb@mdpi.com)

[mdpi.com/journal/cimb](https://mdpi.com/journal/cimb)





# Current Issues in Molecular Biology

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
cimb](https://mdpi.com/journal/cimb)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,  
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,  
New Zealand

---

#### Author Benefits

##### High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,  
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and  
other databases.

##### Rapid Publication:

manuscripts are peer-reviewed and a first decision is  
provided to authors approximately 17.8 days after  
submission; acceptance to publication is undertaken in 2.7  
days (median values for papers published in this journal in  
the first half of 2025).

##### Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and  
reviewer names are published annually in the journal.